Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2008 1
2009 1
2014 2
2015 1
2018 3
2020 1
2021 3
2022 9
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Qiang N, et al. Among authors: ogawa k. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001386
Synthesis of cynaropicrin-d(4).
Sato T, Hara S, Sato M, Ogawa K, Adams M, Usuki T. Sato T, et al. Among authors: ogawa k. Bioorg Med Chem Lett. 2015 Dec 1;25(23):5504-7. doi: 10.1016/j.bmcl.2015.10.065. Epub 2015 Oct 23. Bioorg Med Chem Lett. 2015. PMID: 26520660
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Itobayashi E, Atsukawa M, Kato J, Kato N. Kanzaki H, et al. Among authors: ogawa k. Drugs Real World Outcomes. 2023 Dec;10(4):513-520. doi: 10.1007/s40801-023-00379-x. Epub 2023 Jul 19. Drugs Real World Outcomes. 2023. PMID: 37466822 Free PMC article.
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Matsumoto S, Arai T, Motohashi S, Kato N. Ogawa K, et al. Anticancer Res. 2023 Mar;43(3):1043-1052. doi: 10.21873/anticanres.16249. Anticancer Res. 2023. PMID: 36854524
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.
Kondo T, Fujiwara K, Nakagawa M, Fujimoto K, Yumita S, Ishino T, Ogawa K, Iwanaga T, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Kato J, Kato N. Kondo T, et al. Among authors: ogawa k. Sci Rep. 2023 Jul 17;13(1):11524. doi: 10.1038/s41598-023-38377-2. Sci Rep. 2023. PMID: 37460776 Free PMC article.
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S, Ogasawara S, Nakagawa M, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kogure T, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Kato J, Kato N. Yumita S, et al. Among authors: ogawa k. BMC Gastroenterol. 2023 Mar 31;23(1):101. doi: 10.1186/s12876-023-02731-5. BMC Gastroenterol. 2023. PMID: 37003980 Free PMC article.
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Nakagawa M, et al. Among authors: ogawa k. Cancer. 2023 Feb 15;129(4):590-599. doi: 10.1002/cncr.34559. Epub 2022 Nov 24. Cancer. 2023. PMID: 36426410 Free article.
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N. Ma Y, et al. Among authors: ogawa k. Int J Mol Sci. 2022 Oct 10;23(19):12015. doi: 10.3390/ijms231912015. Int J Mol Sci. 2022. PMID: 36233317 Free PMC article.
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.
Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, Ma Y, Zhang J, Kogure T, Yumita S, Ishino T, Ogawa K, Kan M, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kanda T, Maruyama H, Mimura N, Honda T, Murayama T, Nakamura H, Kato N. Iwanaga T, et al. Among authors: ogawa k. Biochem Biophys Res Commun. 2023 Jan 29;642:192-200. doi: 10.1016/j.bbrc.2022.12.025. Epub 2022 Dec 10. Biochem Biophys Res Commun. 2023. PMID: 36586187
32 results